DIA 2017

Core Interest Area		Topic Areas Encompassed
1	**Data/Big Data/ eHealth**	Informatics, data standards and standardization, data management, data quality, data systems; data integration, compliance, bioethics
2	**Disruptive Innovation**	Innovative methods, innovative science and technology, innovative therapies such as stem cells, regenerative therapies, gene therapies, etc.
3	**Medical Affairs and Scientific Communication**	Medical information; medical science liaison; medical writing; medical affairs roles throughout product life cycle, stakeholder management, advisory boards
4	**Patient Engagement**	Patient-centric practices/engagement, patient advocacy, culture, operationalization, metrics, guidelines/tools
5	**Regulatory**	Global and US advertising and promotional regulations and laws; regulatory operation best practices; regulatory intelligence; developments in regulatory science; eSubmissions; regulatory document management, biosimilars, combination products, companion diagnostics; compliance, regulatory writing; global regulatory
6	**Safety and Pharmacovigilance**	Safety/pharmacovigilance best practices; guideline updates; benefit-risk assessment; risk-based monitoring; document management, biosimilars; post-market safety considerations; combination products; companion diagnostics; compliance
7	**Special Populations**	Rare disease, pediatrics, women's health, pregnancy/lactation, aging
8	**Strategic Planning, Execution, Partnerships**	Portfolio management, project management, transformative partnerships, funding; product life cycle planning, global commercialization considerations
9	**Translational Science: Preclinical, Clinical, and Product Development**	**Preclinical:** Discovery; specific therapeutic area basic research; pharmacodynamics; pharmacokinetics; toxicology testing; absorption, distribution, metabolism, excretion (ADME); gene editing **Clinical Research:** Specific therapeutic areas; precision medicine; clinical trial data disclosure; clinical operations– clinical trial recruitment and retention, patient engagement, site management; clinical trial data disclosure; collaborations; bioethics; study endpoints/COAs (patient-reported outcome [PRO] measures, clinician-reported outcome [CLINRO] measures, observation-reported outcome [OBSRO] measures, and performance outcome [PERFO] measures; COA compendium); adaptive design; Bayesian statistics; informatics; bioinformatics; compliance
10	**Value and Access**	Comparative effectiveness research, health technology assessment, real-world outcomes, value-based health care; drug pricing, reimbursement and access; commercialization; drug product life cycle considerations